Norway· NO-ID_33AD6384-926A-4F5A-BDB9-BC24A1461C2B
Glyxambi
A linagliptin and empagliflozin product containing linagliptin + empagliflozin, registered in Norway by Boehringer Ingelheim International GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Linagliptin and empagliflozin is registered in 13 of 19 countries.
Countries holding a registration under ATC A10BD19 (linagliptin and empagliflozin), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Linagliptin and empagliflozin · ATC A10BD19
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Linagliptin + Empagliflozin
- Manufacturer
- Boehringer Ingelheim International GmbH
- Country
- Norway (NO)
- ATC code
- A10BD19
- ATC class
- Linagliptin and empagliflozin
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_33AD6384-926A-4F5A-BDB9-BC24A1461C2B
- no_varenummer47681490 x 1NOK 2415.1
- gtin4048846012678
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Linagliptin and empagliflozin in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGLYXAMBIBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- SpainGLYXAMBI 10 MG/5 MG COMPRIMIDOS RECUBIERTOS CON PELICULABoehringer Ingelheim International Gmbh
- FinlandGlyxambiBoehringer Ingelheim International GmbH
- United KingdomGlyxambi 10mg/5mg tabletsBoehringer Ingelheim Ltd
- IrelandGlyxambi 10 mg/5 mg film-coated tabletsBoehringer Ingelheim International GmbH
- IcelandGlyxambiBoehringer Ingelheim International GmbH*
- NetherlandsGlyxambi 10 mg/ 5 mg, filmomhulde tablettenBoehringer Ingelheim International GmbH
- United StatesGlyxambiBoehringer Ingelheim Pharmaceuticals, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Glyxambi
- Liechtenstein · Glyxambi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0d495bfa-bc6e-4ab1-aaa0-259ec40d10a6 GET /v1/drugs/0d495bfa-bc6e-4ab1-aaa0-259ec40d10a6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett, filmdrasjert",
"source": "fest",
"status": "A",
"atc_name": "Linagliptin og empagliflozin",
"merkevare_id": "ID_33AD6384-926A-4F5A-BDB9-BC24A1461C2B",
"name_form_strength": "Glyxambi tab 25 mg/5 mg",
"prescription_group": "C"
}See everything about linagliptin and empagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.